Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

749.47
+7.781.05%
Post-market: 749.470.00000.00%19:59 EDT
Volume:553.09K
Turnover:414.83M
Market Cap:79.23B
PE:18.02
High:757.98
Open:744.67
Low:744.02
Close:741.69
52wk High:821.11
52wk Low:476.49
Shares:105.72M
Float Shares:103.30M
Volume Ratio:0.75
T/O Rate:0.54%
Dividend:3.61
Dividend Rate:0.48%
EPS(TTM):41.59
EPS(LYR):41.48
ROE:14.87%
ROA:5.91%
PB:2.53
PE(LYR):18.07

Loading ...

Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains

Dow Jones
·
6 hours ago

Regeneron to report first-quarter 2026 results; conference call and webcast set for 8:30 a.m. ET

Reuters
·
6 hours ago

Regeneron, Sanofi get approval for Dupixent to treat bullous pemphigoid in Japan

TIPRANKS
·
Mar 24

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

GlobeNewswire
·
Mar 24

Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment

Reuters
·
Mar 23

Regeneron (REGN) Receives a Buy from Goldman Sachs

TIPRANKS
·
Mar 23

Assessing Regeneron Pharmaceuticals (REGN) Valuation After Recent Weak Share Momentum And Franchise Outlook

Simply Wall St.
·
Mar 22

Is It Time To Revisit Regeneron (REGN) After Recent Share Price Pullback?

Simply Wall St.
·
Mar 21

Analysts Offer Insights on Healthcare Companies: Electrocore (ECOR) and Regeneron (REGN)

TIPRANKS
·
Mar 20

Get an Lp(a) test - and 3 other things you must do now for heart health

Dow Jones
·
Mar 19

Wells Fargo Adjusts Price Target on Regeneron Pharmaceuticals to $825 From $800, Maintains Equalweight Rating

MT Newswires Live
·
Mar 19

Formycon AG settles aflibercept biosimilar patent litigation with Regeneron and Bayer

Reuters
·
Mar 19

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
Mar 19

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Mar 17

FDA Approves Eylea Hd for Rare Pediatric Disease, Redeeming Priority Review Voucher - Federal Register Website

THOMSON REUTERS
·
Mar 12

FDA: Determined Supplemental Application for Eylea Hd, Approved Nov 19, 2025, Meets Criteria for Redeeming Priority Review Voucher

THOMSON REUTERS
·
Mar 12

Mesoblast appoints Teresa Montagut as Head of Clinical Development and Medical Affairs

Reuters
·
Mar 12

Jefferies Remains a Buy on Regeneron (REGN)

TIPRANKS
·
Mar 11

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

Dow Jones
·
Mar 11

Jefferies Adjusts Price Target on Regeneron Pharmaceuticals to $890 From $885, Maintains Buy Rating

MT Newswires Live
·
Mar 11